SIR-2446 is under clinical development by Sironax and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIR-2446’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SIR-2446 overview

SIR-2446 is under development for the treatment of inflammatory diseases such as Alzheimer's disease and multiple sclerosis. The drug candidate is administered orally as capsule. It acts by targeting receptor interacting serine/threonine protein kinase 1 (RIP1).

Sironax overview

Sironax is a pharmaceuticals and healthcare company discovering transformational therapies to degenerative disease patients. The company is headquartered in Beijing City, Beijing, China.

For a complete picture of SIR-2446’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.